A424870 Stock Overview

An immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. More details

A424870 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

ImmuneOncia Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ImmuneOncia Therapeutics
Historical stock prices
Current Share Price	₩5,880.00
52 Week High	₩8,300.00
52 Week Low	₩5,500.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-21.60%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	A424870	KR Professional Services	KR Market
7D	n/a	-3.2%	-1.3%
1Y	n/a	-4.0%	-7.1%

Return vs Industry: Insufficient data to determine how A424870 performed against the KR Professional Services industry.

Return vs Market: Insufficient data to determine how A424870 performed against the KR Market.

Price Volatility

Is A424870's price volatile compared to industry and market?
A424870 volatility
A424870 Average Weekly Movement	n/a
Professional Services Industry Average Movement	5.5%
Market Average Movement	6.2%
10% most volatile stocks in KR Market	12.5%
10% least volatile stocks in KR Market	3.0%

Stable Share Price: A424870's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A424870's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	n/a	Heung Tae Kim	www.immuneoncia.com

ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer. The company also develops non clinical products, which includes IMC-201, a CD47xPD-L1 dual antibody based immunotherapy; and IMC-202, a PD-L1xTIGIT dual antibody based immunotherapy.

ImmuneOncia Therapeutics, Inc. Fundamentals Summary

How do ImmuneOncia Therapeutics's earnings and revenue compare to its market cap?
A424870 fundamental statistics
Market cap	₩483.29b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A424870 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A424870 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A424870 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/23 15:52
End of Day Share Price	2025/05/23 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ImmuneOncia Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.